Preview

Проблемы Эндокринологии

Расширенный поиск

Глибенкламид: доказанные факты, перспективы, дискуссии

https://doi.org/10.14341/probl201359357-62

Полный текст:

Аннотация

Глибенкламид - препарат, эффективность и безопасность которого подтверждена 40-летней клинической практикой, несмотря на дискуссии по поводу кардиоваскулярного риска. Однако следует отметить перспективы применения глибенкламида в терапии травматических и ишемических повреждений ЦНС, связанные с наличием большого количества экспериментальных публикаций и проведения клинических исследований.

Об авторе

N Chepliaeva



Список литературы

1. Дедов И.И., Шестакова М.В. Сахарный диабет. Диагностика, лечение, профилактика. М 2011; 801.

2. Seino S., Shibasaki T., Minami K. Pancreatic beta-cell signaling: toward better understanding of diabetes and its treatment. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 6: 563-577.

3. Babenko A.P., Gonzalez G., Bryan J. Two regions of sulfonylurea receptor specify the spontaneous bursting and ATP inhibition of KATP channel isoforms. J Biol Chem 1999; 274: 17: 11587-11592.

4. Proks P., Reimann F., Green N., Gribbl F., Ashcroft F. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002; 51: Suppl 3: S368-S376.

5. Gribble F.M., Tucker S.J., Seino S., Ashcroft F.M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998; 47: 9: 1412-1418.

6. Doёrschner H., Brekardin E., Uhde I. Stoichiometry of Sulfonylurea-Induced ATP-Sensitive Potassium Channel Closure. Molecular Pharmacol 1999; 55: 1060-1066.

7. Day C. ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. Br J Diabet Vasc Dis 2012; 12: 3: 146-151.

8. Amiel S.A., Dixon T., Mann R. et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254.

9. Kahn S.E., Haffner S.M., Heise M.A. Nissen S.E., Wolski K. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.

10. Aquilante C.L. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 2010; 8: 3: 359-372.

11. Wei H., Dalton C., Di Maso M., Kanfer I., Lubenberg R. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharmac Biopharmac 2008; 69: 1046-1056.

12. Карпов О.И. Микронизированный глибенкламид - модификация лекарственной формы и кинетики, нацеленная на результат. РМЖ 2006; 26: 3-6.

13. Blume H., Ali S.L., Siewert M. Pharmaceutical Quality of Glibenclamide Products A Multinational Postmarket Comparative Study. Drug Develop Indust Pharm 1993; 19: 20: 2713-2741.

14. Chaudhary A., Nagaich U., Gulati N., Sharma V.K., Khosa R.L. et al. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Advanc Pharm Educ Res 2012; 2: 1: 32-67.

15. Rendell M. The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Drugs 2004; 64: 12: 1335-1339.

16. Carlson R.F., Isley W.L., Ogrinc F.G., Klobucar T.R. et al. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther 1993; 15: 5: 788-796.

17. Bell D.S.H. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 2: 185-186.

18. O'Rourke B. Myocardial KATP Channels in Preconditioning. Circulat Res 2000; 87: 845-855.

19. Riveline J.P., Danchin N., Ledru F., Varroud-Vial M., Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222.

20. Fisman E.Z., Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabet 2009; 8: 38. doi: 10.1186/1475-2840-8-38.

21. Loubania M., Fowlera A., Standenb N.B. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 515: 142-149.

22. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 2: 169-174.

23. McAlister F.A., Eurich D.T., Majumdar S.R., Johnson J.A. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008; 10: 703-708.

24. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., Holmes D.R. Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction. J Am Coll Cardiol 1999; 33: 119-124.

25. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 15: 1900-1908.

26. Meier J.J., Deifuss S., Klamann A. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes: the LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabet 2003; 111: 344-350.

27. Selvin E., Bolen S., Yeh H.-C., Wiley C., Wilson L.M., Marinopoulos S.S., Feldman L., Vassy J., Wilson R., Bass E.B., Brancati F.L. Cardiovascular Outcomes in Trials of Oral Diabetes Medications:A Systematic Review. Arch Int Med 2008; 168: 19: 2070-2080.

28. Simard J.M., Woo S.K., Bhatta S., Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 2008; 8: 1: 42-49.

29. Simard J.M., Woo S.K., Schwartzbauer G.T., Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cerebral Blood Flow Metabol 2012; 32: 1699-1717.

30. Chen M., Dong Y., Simard J.M. Functional Coupling between Sulfonylurea Receptor Type 1 and a Nonselective Cation Channel in Reactive Astrocytes from Adult Rat Brain. J Neurosci 2003; 23: 24: 8568-8577.

31. Patel A.D., Gerzanich V., Geng Z. Glibenclamide Reduces Hippocampal Injury and Preserves Rapid Spatial Learning in a Model of Traumatic Brain Injury. J Neuropathol Exper Neurol 2010; 69: 2: 1177-1190.

32. Simard J.M., Yurovsky V., Tsymbalyuk N. et al. Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke. Stroke 2009; 40: 2: 604-609.

33. Kunte H., Schmidt S., Eliasziw M. Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke. Stroke 2007; 38: 2526-2530.


Для цитирования:


. Глибенкламид: доказанные факты, перспективы, дискуссии. Проблемы Эндокринологии. 2013;59(3):57-62. https://doi.org/10.14341/probl201359357-62

For citation:


Chepliaeva N.I. Glibenclamide: proven facts, perspectives, discussions. Problems of Endocrinology. 2013;59(3):57-62. (In Russ.) https://doi.org/10.14341/probl201359357-62

Просмотров: 79


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)